Orphazyme reports positive results from full data set of Phase II/III arimoclomol trial in Niemann-Pick disease Type C (NPC)
January 30, 2019 01:14 ET
|
ORPHAZYME A/S
Orphazyme A/SCompany announcement No....
Orphazyme reports encouraging arimoclomol clinical trial top-line data in Niemann-Pick disease Type C (NPC)
September 28, 2018 01:00 ET
|
ORPHAZYME A/S
Orphazyme A/SCompany announcement No....
Orphazyme to Present at 25th NPUK Annual Family Conference 2018
September 20, 2018 09:19 ET
|
ORPHAZYME A/S
Orphazyme A/SInvestor news No....
Sucampo to Host 2017 R&D Day on November 16 in New York
November 09, 2017 17:48 ET
|
Sucampo Pharmaceuticals Inc
ROCKVILLE, Md., Nov. 09, 2017 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc. (Sucampo) (NASDAQ:SCMP), a global biopharmaceutical company, today announced that it will host its 2017 R&D Day...
Sucampo Reports Second Quarter 2017 Financial Results
August 02, 2017 06:30 ET
|
Sucampo Pharmaceuticals Inc
Patent Issued for Pipeline Compound VTS-270 for Niemann-Pick Disease Type C1 Diluted EPS Loss of $3.92 Resulting from $186.6M IP R&D Second Quarter Charge Due to Accounting Treatment of Vtesse...
Sucampo Pharmaceuticals Announces Issuance of New Patent for VTS-270
June 13, 2017 16:30 ET
|
Sucampo Pharmaceuticals Inc
ROCKVILLE, Md., June 13, 2017 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP), a global biopharmaceutical company, today announced that the U.S. Patent and Trademark Office...
Sucampo Acquires Vtesse Inc.
April 03, 2017 06:30 ET
|
Sucampo Pharmaceuticals Inc
Transaction Valued at $200 Million Upfront Diversifies Pipeline with Late Stage Program in Niemann-Pick Disease Type C1 (NPC-1) Increases Company Focus on Specialized Diseases with High Unmet Need ...